This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study designs and other criteria for inclusion in the review
It was unclear whether clinical evidence was derived from a systematic review of the literature. Limited information on the design and other features of the primary studies was provided. Sensitivity and specificity of HPV testing were taken from a meta-analysis. Survival from invasive cancer and mortality due to other causes were taken from UK life tables.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Not reported.
Number of primary studies included
Nine studies were used as the source of evidence.
Methods of combining primary studies
Primary estimates were not combined as each study provided a set of estimates.
Investigation of differences between primary studies
Results of the review
The following attendance rates were estimated: 81% (range: 76% -85%) for routine smear, 79% (range: 77% -80%) for repeat smear (age <35); 85% (range: 84% -87%) for repeat smear (age >/= 35), 95% (range: 97% -93%) for colposcopy (age <35), and 93% (range: 90% -96%) for colposcopy (age >/=35).
The prevalence of HPV infection at age 15 was 0.1, while the prevalence of CIN-1 at age 15 was 0.01. The regression rate from CIN2/3 to CIN1 or healthy was 0.035 (range: 0.0292 -0.056).
The proportion of CIN2/3 reverting to healthy was 0.5 (range: 0 -0.5).
The progression rate from CIN2/3 to invasive cancer was 0.025 (range: 0.018 -0.034).
The sensitivity and specificity of HPV testing were, respectively, 0.948 (range: 0.927 -0.969) and 0.673 (range: 0.582 -0.764).
The effectiveness of colposcopy was 90% (range: 80% -100%).
The progression rate from stage I to stage II was 0.13. The probability of symptoms in stage I was 0.08. 
Methods used to derive estimates of effectiveness
The authors made some assumptions that were used in the decision model.
Estimates of effectiveness and key assumptions
For all strategies, 90% of cases of invasive cancer were detected at each screening round. All colposcopies were
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Measure of benefits used in the economic analysis
The summary benefit measure was the number of life-years (LYs) that were estimated using the decision model. A 3.5% annual discount rate was applied in the first 30 years and 3% thereafter.
Direct costs
The analysis of costs took the perspective of the NHS and included the following direct medical costs: conventional cytology, liquid based cytology, HPV test, colposcopy (for patients with and without CIN), and cancer care costs. Costs of diagnostic tests included equipment, consumables, and staff. Unit costs were presented for most items but costs of cancer care were given as macro-categories and were stage-dependent. Limited information on resource consumption was provided. Costs of cancer care were estimated from a previous UK study. Other costs came from market prices and typical NHS sources. Resource consumption was mainly derived from the 3 NHS pilot sites. Discounting was relevant as lifetime costs were estimated, and a 3.5% annual discount rate was applied in the first 30 years and a 3% thereafter.
Costs were inflated to 2001/2002 values using the NHS Health and Community Price Index.
Statistical analysis of costs
Costs were treated deterministically in the base case but probabilistic distributions were assigned in the sensitivity analysis.
Indirect Costs
Indirect costs were not included.
Currency
UK pounds sterling (). Some costs were also reported in Euros (EUR) and US dollars ($) but exchange rates were not given.
Sensitivity analysis
Univariate sensitivity analyses were carried out to assess the impact of individual model inputs on total costeffectiveness ratios. Alternative values tested in the analysis were derived from the literature. A probabilistic sensitivity analysis was also performed and all model inputs were assigned a probabilistic distribution. Beta distributions were mainly used for probabilities of events, while gamma distributions were applied to economic data. The results of the stochastic simulation were presented using a cost-effectiveness acceptability curve, which showed the optimal strategy at different values the service payer would be willing to pay for a gain in life years.
Estimated benefits used in the economic analysis
In comparison with conventional cytology, the LYs gained were 0.0019 with strategy A, 0.0034 with strategy D, 0.0039 with strategy C, 0.0049 with strategy E, and 0.0050 with strategy B.
The lifetime risk of death from invasive cancer was also reported and was 0.0049 with strategy A, 0.0045 with strategy B, 0.0046 with strategies C and D, and 0.0045 with strategy E.
Cost results
In comparison with conventional cytology, the extra costs were 9.9 with strategy A, 12.7 with strategy D, 20.2 with strategy C, 19.1 with strategy E, and 19.9 with strategy B. The numbers of smears, HPV tests, colposcopies, and treatments for invasive cancers were also reported.
